iopamidol NDC 70436-126

NDC codes

FDA NDC Directory

Product NDC (as listed)70436-126Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70436-0126Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70436-126-34	70436012634	15 mL in 1 VIAL, SINGLE-DOSE (70436-126-34)Marketed from Jul 20, 2023
70436-126-82	70436012682	150 mL in 1 CARTON (70436-126-82)Marketed from Jul 20, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): iopamidol
Generic name (nonproprietary): iopamidol
Active ingredients: Iopamidol — 612 mg/mL
Dosage form: Injection, Solution
Route: Intrathecal
Labeler: Slate Run Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215382
Marketing start: Jul 20, 2023
Listing expires: Dec 31, 2027
Other FDA classes: X-Ray Contrast Activity (Mechanism)
Identifiers: Product ID 70436-126_5821e051-f3a4-b435-e063-6294a90a62b9SPL ID 5821e051-f3a4-b435-e063-6294a90a62b9SPL set ID 0b9e0d24-c6ca-4e22-9422-936e9d475eaaUNII JR13W81H44UPC 0370436126828, 0370436124824, 0370436124527
Pharmacologic class: Radiographic Contrast Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N470436012634 followed by a unit qualifier and the quantity

Package 70436-0126-34. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 23, 2026.

Indications (excerpt from the label)

Iopamidol injection for intrathecal administration is indicated for: Lumbar and thoracic myelography, and computed tomography (CT) myelography in adults and pediatric patients aged 2 years and older Cervical and total columnar myelography and CT myelography in adults CT cisternography in adults Specific concentrations of iopamidol injection are recommended for each type of imaging procedure [see Dosage and Administration ( 2.2 , 2.3 )]. Iopamidol injection is a radiographic contrast agent indicated for: Lumbar and thoracic myelography and computed tomography (CT) myelography in adults and pediatric patients aged 2 years and older Cervical and total columnar myelography in adults CT cisternog…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215382

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215382
Product	Strength	Form · route	Labeler	Product NDC
iopamidol	Iopamidol 408 mg/mL	Injection, SolutionIntrathecal	Slate Run Pharmaceuticals, LLC	70436-124